Nuplazid Safety Review: Blast From the Past Or Preview Of Future Terrors?
Fueled by Congress, media attention, reevaluation of Acadia's Parkinson's drug feels like a scandal from pharma's primary care era – but is also a glimpse of what things might look like for industry if Democrats retake the House.
You may also be interested in...
The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.
Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.
The latest drug development news and highlights from our US FDA Performance Tracker.